Peter Feinberg’s Post

We’re excited to share we presented our sub-analysis comparing acoramidis to placebo in Stage 4 chronic kidney disease & results from a pre-specified sensitivity analysis from ATTRibute-CM, our Phase 3 study of acoramidis in ATTR-CM alongside 3 posters on our positive results in ATTRibute-CM at the European Society of Cardiology Heart Failure. Learn more about the data: https://bit.ly/4dE9zPm

We're grateful to all of the mothers we interact with: the ones persevering as patients, the ones caring and advocating for their loved ones, the ones creating therapies for those in need, and the ones who inspire us every day. Happy Mother's Day!

In the second part of our OnRare episode with Eric, we hear more about his experience living with transthyretin amyloidosis (ATTR). He explains how impactful becoming involved with the ATTR community has been for himself and others. Listen to the full episode here: https://bit.ly/46IBOYm

At this year’s European Society of Cardiology Heart Failure, we will be presenting a sub-analysis in chronic kidney disease from ATTRibute-CM, our Phase 3 study in patients with ATTR-CM as well as sharing moderated posters on data from the trial. Join us onsite to learn more.

This year at the European Congress of Endocrinology 2024 hosted by the European Society of Endocrinology, our team will be sharing 18 month results from our Phase 2 clinical trial in ADH1, our clinical trial design for CALIBRATE, our Phase 3 study of encaleret for people with ADH1, and insights on our genetic testing program. Learn more here: https://bit.ly/3LPOvt9 #ECE2024

Today we announced our 1Q2024 financial results and recent corporate highlights. See our press release for details: https://buff.ly/4afshts #UniversalRAS #UniversaRAF #MAPKPathway #SolidTumors #CancerResearch #TargetedOncology #MetastaticCancer #AdvancedCancer

Our transthyretin amyloidosis (ATTR) team is heading to ESC Heart Failure hosted by European Society of Cardiology! This year, we will be sharing updates from our ATTRibute-CM Phase 3 trial in one oral presentation and three moderated poster presentations. We will also be supporting a Satellite Symposium with leading physicians in the cardiology space. Check out our website to learn about our latest news: bridgebio.com/what-is-attr 

We're thrilled to announce the launch of BridgeBio Oncology Therapeutics (BBOT) to accelerate the development of our #oncology portfolio. Led by Eli Wallace, Ph.D., as chief executive officer and Pedro J. Beltran, Ph.D., as chief scientific officer, BBOT will advance three initial programs and continue to undertake a robust discovery-stage research program focused on targeting additional oncogenic drivers within the RAS and PI3K pathways. Learn more about the news: https://bit.ly/3WnSmDh